Trecento Santé is an open-ended mutual fund (UCITS IV) that invests in shares of international companies from the healthcare sector (including pharmaceutical, biotechnology, diagnostics and medical technology companies, management of hospitals and health centers).

Its objective, for the recommended investment horizon of 5 years, is to achieve a net annualised return of more than 7% (share classes R EUR, R CHF and R USD) and more than 8% for the share class I EUR.

N.B: an institutional share class in euros (I EUR) has been launched on 12/31/2018.

R EUR Share – Performances at 19/09/2019
NAVYTD1 month1 year3 yearsCreation
1 786,80€
6,52%
+0,53%
-1,68%
+14,97%
+78,68%
NAV
1 786,80€
YTD 6,52%
1 month +0,53%
1 year -1,68%
3 years +14,97%
Creation
+78,68%
R USD Share – Performances at 19/09/2019
NAVYTD1 month1 year3 yearsCreation (17/01/2017)
1 167,17 $
2,45%
+0,18%
--%
--%
+16,72%
NAV
1 167,17 $
YTD2,45%
1 month+0,18%
1 year--%
3 years--%
Creation (17/01/2017)
+16,72%
R CHF Share – Performances at 19/09/2019
NAVYTD1 month1 year3 yearsCreation (17/01/2017)
1 172,12 CHF
2,91%
+1,42%
--%
--%
+17,21%
NAV
1 172,12 CHF
YTD2,91%
1 month+1,42%
1 year--%
3 years--%
Creation (17/01/2017)
+17,21%

ISIN code

R EUR Share – FR0011319664
I EUR Share – FR0013392461
R USD Share – FR0013224391
R CHF Share – FR0013224409

Legal form • Mutual Fund under the French law (FCP), UCITS IV compliant

Currency • Euro (€)

Launch date • 14/12/12

AMF Classification • International equities

Recommended investment horizon • 5 years

Valuation Period • Daily

Dividend Policy • Accumulation

Subscriptions/Redemptions• Cut-off: 16.30

Custodian • CACEIS Bank

Fund valuation • CACEIS Fund Administration

Auditors • Mazars

FATCA Status • Deemed-compliant FFI – Non reporting IGA FFI


Management fees
• 2% (incl. taxes) maximum for the R shares

• 1% (incl. taxes) maximum for the I EUR share

Entry fee • 2.5% (incl. taxes) maximum

Exit fee • 0%

aliceAlice LHABOUZ

Founder & CEO

Alice LHABOUZ began her career at the Corporate Finance Division of Autorité des Marchés Financiers (AMF).

After working as a Buy-Side Financial Analyst at Richelieu Finance, Alice LHABOUZ joined La Financière Meeschaert in 2005 as a Private Portfolio Manager for French high-net-worth individuals and families.

In 2011, she founded Trecento Asset Management.

Alice LHABOUZ heads the company and, with Christophe POUCHOY, manages the collective investment funds (mutual or dedicated) and is also the manager of discretionary investment mandates of private clients.

christopheChristophe POUCHOY

Managing Director & Chief Investment Officer

Christophe POUCHOY graduated from HEC Paris.

He started his career in London at the investment bank Lehman Brothers where he was advising European financial companies and governments on their financing and regulatory capital issuance. From October 2008, he held similar responsibilities at the investment bank Nomura International.

Christophe POUCHOY joined Trecento AM in 2013 and was promoted co-fund manager in 2014.

Christophe POUCHOY is currently Managing Director & Chief Investment Officer of Trecento AM. In that respect, he notably acts as Fund Manager of all collective investment funds (mutual or dedicated) and assists Alice LHABOUZ for the discretionary investment management of private clients’ assets.

A leading healthcare expert committee, supporting the management team

This committee provides its experience and expertise to the management team to refine its product and sector market understanding.

+ Performance
R EUR Share – Performances at 19/09/2019
NAVYTD1 month1 year3 yearsCreation
1 786,80€
6,52%
+0,53%
-1,68%
+14,97%
+78,68%
NAV
1 786,80€
YTD 6,52%
1 month +0,53%
1 year -1,68%
3 years +14,97%
Creation
+78,68%
R USD Share – Performances at 19/09/2019
NAVYTD1 month1 year3 yearsCreation (17/01/2017)
1 167,17 $
2,45%
+0,18%
--%
--%
+16,72%
NAV
1 167,17 $
YTD2,45%
1 month+0,18%
1 year--%
3 years--%
Creation (17/01/2017)
+16,72%
R CHF Share – Performances at 19/09/2019
NAVYTD1 month1 year3 yearsCreation (17/01/2017)
1 172,12 CHF
2,91%
+1,42%
--%
--%
+17,21%
NAV
1 172,12 CHF
YTD2,91%
1 month+1,42%
1 year--%
3 years--%
Creation (17/01/2017)
+17,21%
+ Caracteristics

ISIN code

R EUR Share – FR0011319664
I EUR Share – FR0013392461
R USD Share – FR0013224391
R CHF Share – FR0013224409

Legal form • Mutual Fund under the French law (FCP), UCITS IV compliant

Currency • Euro (€)

Launch date • 14/12/12

AMF Classification • International equities

Recommended investment horizon • 5 years

Valuation Period • Daily

Dividend Policy • Accumulation

Subscriptions/Redemptions• Cut-off: 16.30

Custodian • CACEIS Bank

Fund valuation • CACEIS Fund Administration

Auditors • Mazars

FATCA Status • Deemed-compliant FFI – Non reporting IGA FFI


Management fees
• 2% (incl. taxes) maximum for the R shares

• 1% (incl. taxes) maximum for the I EUR share

Entry fee • 2.5% (incl. taxes) maximum

Exit fee • 0%

+ Documents
+ The Fund Managers

aliceAlice LHABOUZ

Founder & CEO

Alice LHABOUZ began her career at the Corporate Finance Division of Autorité des Marchés Financiers (AMF).

After working as a Buy-Side Financial Analyst at Richelieu Finance, Alice LHABOUZ joined La Financière Meeschaert in 2005 as a Private Portfolio Manager for French high-net-worth individuals and families.

In 2011, she founded Trecento Asset Management.

Alice LHABOUZ heads the company and, with Christophe POUCHOY, manages the collective investment funds (mutual or dedicated) and is also the manager of discretionary investment mandates of private clients.

christopheChristophe POUCHOY

Managing Director & Chief Investment Officer

Christophe POUCHOY graduated from HEC Paris.

He started his career in London at the investment bank Lehman Brothers where he was advising European financial companies and governments on their financing and regulatory capital issuance. From October 2008, he held similar responsibilities at the investment bank Nomura International.

Christophe POUCHOY joined Trecento AM in 2013 and was promoted co-fund manager in 2014.

Christophe POUCHOY is currently Managing Director & Chief Investment Officer of Trecento AM. In that respect, he notably acts as Fund Manager of all collective investment funds (mutual or dedicated) and assists Alice LHABOUZ for the discretionary investment management of private clients’ assets.

+ The healthcare committee
A leading healthcare expert committee, supporting the management team

This committee provides its experience and expertise to the management team to refine its product and sector market understanding.

Past performance is not an indication of future results and may vary over time. Performances are calculated net of fees.
Data sources: Trecento AM

Trecento Santé on vidéo
The Healthcare Club

A healthcare club source of technology watch and skill sharing.. Each health professional subscriber is invited to join the Trecento healthcare club to share with us his “field” experience

Trecento Santé on Twitter
#Kadcyla (HER2-positive early #breast #cancer) from #Genentech (#Roche unit) met primary endpoint in a Ph III study… https://t.co/YpSjAHlTOU
@genentech (filiale de @Roche) a annoncé des résultats positifs en Ph III pour le #Kadcyla (#cancer du #sein HER-2… https://t.co/hv58Kws4Z4
1
#Capio recommended shareholders to accept #RamsayGDS new takeover price at 58SEK per share (+20% from the previous… https://t.co/scqePlFGlW
#Capio semble se satisfaire de la révision à la hausse de l'offre d'achat par @RamsayGDS (58 SEK par action) et rec… https://t.co/zDTZZUTfp8
1
#RamsayGDS increases #CAPIO offer price by almost 20% at 58 SEK per share, versus 48.5 #M&A #Healthcare #Services… https://t.co/uisxxeAnaM
@RamsayGDS relève son offre sur #CAPIO de près de 20% à 58 SEK par action, contre 48,5 précédemment… https://t.co/ym0Hb6UEXL
1
#Roche won #US_FDA regulatory approval to sell #Hemlibra (#emicizumab) to the largest portion of #hemophilia patien… https://t.co/2g1ceoWFcv
@Roche obtient le feu vert de la @US_FDA pour la commercialisation d'#Hemlibra (#emicizumab) auprès du plus large g… https://t.co/d6RugV9FBu
1 1
Positive results in a Ph III study for the #Baloxavir #marboxil from #Roche, which aims to treat #Flu patients at r… https://t.co/VNPZRFBWQp
Données positives en Ph III pour le #Baloxavir #marboxil de @Roche destiné à traiter les patients atteints de la… https://t.co/IdRp9AMaMJ
1 2
#Sanofi completes sale of its #Generics division to #Advent International for about 1.9 billion of euros. The Compa… https://t.co/F5tc2EZJDu
@sanofi finalise la cession de sa division #Génériques à #Advent International (Private Equity) pour 1,9 milliard d… https://t.co/lG4Mw8PEUM
1
@AlexionPharma to buy #Symtimmune, biotech company which currently has a treatment for autoimmune hemolytic anemia… https://t.co/1gmWqea2i7
1
@AlexionPharma rachète #Symtimmune, biotech développant notamment un traitement pour l'#anémie hémolytique auto-imm… https://t.co/yY0yZxaVvD
1
At #TCT2018, manufacturers of #cardiologic medical equipment have demonstrated improvements in their equipment and… https://t.co/gsxWH3pn05
Au #TCT2018, les fabricants d'équipements médicaux en #cardiologie ont fait la démonstration d'améliorations de leu… https://t.co/fJ2s8EyeZP
4 4
Diabetics are at increased risk of heart problems, making the #cardiovascular (CV) profile of medicines to treat th… https://t.co/sfW3ABUzbc
1
La prise en compte des événements #cardiovasculaires dans les traitements contre le #diabète devient de plus en plu… https://t.co/gF9mDxk3Na
1 2
RT @Trecento_Robot: @Medtronic rachète @MazorRobotics, spécialiste des #robots #chirurgicaux dans le domaine interventionnel de la #colonne…
2
According to sources familiar with the matter, #Nestlé, #Unilever and #Coca-Cola could buy #Horlicks, a nutrition b… https://t.co/JzJOJJ5oQ5
1